Press release
Myocardial Infarction Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Myocardial Infarction Pipeline
Myocardial Infarction Overview
Myocardial Infarction (MI), colloquially known as "heart attack," is caused by decreased or complete cessation of blood flow to a portion of the myocardium. Myocardial infarction may be "silent" and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death.
Myocardial ischemia symptoms include- chest pain, upper extremity, and mandibular or epigastric discomfort that occurs during exertion or at rest. Myocardial ischemia can also show symptoms such as dyspnea or fatigue, which are known to be ischemic equivalents.
"Myocardial Infarction Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myocardial Infarction Market.
The Myocardial Infarction Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Myocardial Infarction Pipeline Report: https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Myocardial Infarction treatment therapies with a considerable amount of success over the years. Myocardial Infarction Key players such as - NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, Celecor Therapeutic, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, and others are developing therapies for the Myocardial Infarction treatment
• Myocardial Infarction Emerging therapies such as - NVX 308, UMSC01, RPH-104, ATH3G10, Zalunfiban, FDY-5301, Selatogrel, and others are expected to have a significant impact on the Myocardial Infarction market in the coming years.
• In late 2019, Idorsia entered into a global development agreement with Antares Pharma, a US-based leader in autoinjector and rescue pen technologies, to design and customize an autoinjector for selatogrel. The Antares autoinjector was selected for its robustness, reliability, ease-of-use, and emergency-ready capabilities - key characteristics necessary due to the nature of Acute Myocardial Infarction
• In December 2020, the FDA designated the investigation of selatogrel for the treatment of a suspected Acute Myocardial Infarction (AMI) in adult patients with a history of Acute Myocardial Infarction (AMI) as a "fast-track" development program. This designation is intended to promote communication and collaboration between the FDA and pharmaceutical companies for drugs that treat serious conditions and fill an unmet medical need
• In August 2021, Idorsia Pharmaceuticals initiated a multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Self-administered Subcutaneous Selatogrel for Prevention of All-cause Death and Treatment of Acute Myocardial Infarction in Subjects with a Recent History of Acute Myocardial Infarction
Myocardial Infarction Pipeline Therapeutics Assessment
• Myocardial Infarction Assessment by Product Type
• Myocardial Infarction By Stage and Product Type
• Myocardial Infarction Assessment by Route of Administration
• Myocardial Infarction By Stage and Route of Administration
• Myocardial Infarction Assessment by Molecule Type
• Myocardial Infarction by Stage and Molecule Type
DelveInsight's Myocardial Infarction Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Myocardial Infarction Drugs Under Different Phases of Clinical Development Include:
• NVX 308: NuvOx Pharma
• UMSC01: Ever Supreme Bio Technolog
• RPH-104: R-Pharm
• ATH3G10: Athera Biotechnologies
• Zalunfiban: Celecor Therapeutic
• FDY-5301: Faraday Pharmaceuticals
• Selatogrel: Idorsia Pharmaceuticals
Further Myocardial Infarction product details are provided in the report. Download the Myocardial Infarction pipeline report to learn more about the emerging Myocardial Infarction therapies at: https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Myocardial Infarction Pipeline Analysis:
The Myocardial Infarction pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Myocardial Infarction treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.
• Myocardial Infarction key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Myocardial Infarction market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Myocardial Infarction Pipeline Market Drivers
• Increasing research and development activities
• Increasing number of public initiatives and awareness program on cardiovascular disease
Myocardial Infarction Pipeline Market Barriers
• The lack of emergency care awareness
• The heterogeneity of patients, along with the duration of treatment and modalities
Get a Free Sample PDF Report to know more about Myocardial Infarction Pipeline Assessment- https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of Myocardial Infarction Pipeline Drug Insight
• Coverage: Global
• Key Myocardial Infarction Companies: NuvOx Pharma, Ever Supreme Bio Technolog, R-Pharm, Athera Biotechnologies, Celecor Therapeutic, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, and others
• Key Myocardial Infarction Therapies: NVX 308, UMSC01, RPH-104, ATH3G10, Zalunfiban, FDY-5301, Selatogrel, and others
• Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies
• Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers
Request for Sample PDF Report for Myocardial Infarction Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Myocardial Infarction Report Introduction
2 Myocardial Infarction Executive Summary
3 Myocardial Infarction Overview
4 Myocardial Infarction- Analytical Perspective In-depth Commercial Assessment
5 Myocardial Infarction Pipeline Therapeutics
6 Myocardial Infarction Late Stage Products (Phase II/III)
7 Myocardial Infarction Mid Stage Products (Phase II)
8 Myocardial Infarction Early Stage Products (Phase I)
9 Myocardial Infarction Preclinical Stage Products
10 Myocardial Infarction Therapeutics Assessment
11 Myocardial Infarction Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Myocardial Infarction Key Companies
14 Myocardial Infarction Key Products
15 Myocardial Infarction Unmet Needs
16 Myocardial Infarction Market Drivers and Barriers
17 Myocardial Infarction Future Perspectives and Conclusion
18 Myocardial Infarction Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Myocardial Infarction drugs and therapies- https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Myocardial Infarction Market https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Myocardial Infarction Epidemiology https://www.delveinsight.com/report-store/myocardial-infarction-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Trending Reports:
Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027
To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myocardial Infarction Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies here
News-ID: 2736364 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Myocardial
Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Numb …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual…
Diabetes Epidemic Fuels Myocardial Ischemia Market Growth: An Emerging Driver Tr …
The Myocardial Ischemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Myocardial Ischemia Market?
The myocardial ischemia market has grown strongly. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a CAGR of 7.3%.…
Transforming the Myocardial Ischemia Market in 2025: Diabetes Epidemic Fuels Myo …
What Is the Expected Size and Growth Rate of the Myocardial Ischemia Market?
The market size for myocardial ischemia has demonstrated considerable growth over the last few years. There's a predicted growth from $0.79 billion in 2024 to $0.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historical period can be credited to the use of telemedicine and remote monitoring, the discovery…
Myocardial Infarction Treatment Market Growth and Insights 2024
"The Business Research Company recently released a comprehensive report on the Global Myocardial Infarction Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, Î' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026".
The Global market size of Myocardial Infarction Drugs Market was $XX…
Myocardial Ischemia - Pipeline Review, H1 2017 - Pharmaceutical Report
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm…
